No data to show
XSES
P8A
Market cap56mUSD
Aug 03, Last price
0.36SGD
Name
Cordlife Group Ltd
Chart & Performance
P/E
—
P/S
3.26
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.13%
Rev. gr., 5y
-9.47%
Revenues
28m
-50.04%
Net income
-19m
L
CFO
-11m
L
Profile
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics. It provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening, and newborn genetic screening services. The company also offers preimplantation genetic screening, endometrial receptivity test, paediatric allergen test, and genetic talent test services, as well as moms up, a mobile app for pregnancy and parenting resources. In addition, it provides management, marketing, and property investment services. Cordlife Group Limited was incorporated in 2001 and is headquartered in Singapore.
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||||
Revenues | 27,843 -50.04% | 55,730 1.04% | 55,156 31.33% | ||||||||
Cost of revenue | 52,044 | 56,725 | 54,259 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (24,201) | (995) | 897 | ||||||||
NOPBT Margin | 1.63% | ||||||||||
Operating Taxes | (104) | 692 | 617 | ||||||||
Tax Rate | 68.78% | ||||||||||
NOPAT | (24,097) | (1,687) | 280 | ||||||||
Net income | (18,686) -630.40% | 3,523 -27.91% | 4,887 7.49% | ||||||||
Dividends | (74) | (2,304) | |||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | 1,894 | (5,537) | 1,199 | ||||||||
Long-term debt | 2,956 | 5,197 | 3,235 | ||||||||
Deferred revenue | 64,423 | 67,280 | |||||||||
Other long-term liabilities | 1,002 | 66,787 | 522 | ||||||||
Net debt | (16,634) | (29,652) | (116,234) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (11,312) | 9,796 | 5,944 | ||||||||
CAPEX | (4,160) | (2,273) | (2,396) | ||||||||
Cash from investing activities | (2,810) | (2,631) | 4,431 | ||||||||
Cash from financing activities | 7,165 | (1,860) | (11,675) | ||||||||
FCF | (16,839) | (13,919) | 2,103 | ||||||||
| Balance | |||||||||||
Cash | 60,579 | 65,009 | 65,170 | ||||||||
Long term investments | (39,095) | (35,697) | 55,498 | ||||||||
Excess cash | 20,092 | 26,526 | 117,910 | ||||||||
Stockholders' equity | 151,548 | 170,298 | 228,147 | ||||||||
Invested Capital | 166,417 | 179,418 | 85,738 | ||||||||
ROIC | 0.41% | ||||||||||
ROCE | 0.43% | ||||||||||
| EV | |||||||||||
Common stock shares outstanding | 256,308 | 256,294 | 256,229 | ||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | (19,993) | 3,035 | 4,580 | ||||||||
EV/EBITDA | |||||||||||
Interest | 196 | 268 | 152 | ||||||||
Interest/NOPBT | 16.95% | ||||||||||